B&M: Nigel you’re the Chief Investment Officer within Imperial Innovations and responsible for the Group’s investment activities, but what does that equate to on a day-to-day basis?…
This is the third of 4 weekly Polls hosted throughout July that will accompany the August edition of Drugs&Dealers Magazine ‘Lost in Translation: Tech Transfer and Start-up Capital’. The results from this Poll will…
How to Raise Capital: What Can We Learn from Skyepharma? B&M: Do you want to start by quickly giving us your company story, your elevator pitch? PG: The business is…
The biopharma funding and investment climate definitely seems to have picked up for over the past year. Still, many biotech CEO’s fret about the dearth of opportunities – particularly for…
Tim Mitchell, CEO, Sareum, an AIM listed biotech, spoke to me about his fears for the UK biotech industry. What he had to say was quite revealing. Understanding the investment…
